" class="no-js "lang="en-US"> David (Dave) Fredrickson - Medtech Alert
Monday, August 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Fredrickson

David (Dave) Fredrickson

About David (Dave) Fredrickson

Biopharmaceutical executive passionate about leading with purpose and uniting diverse talents while working urgently to impact the lives of patients.

Expertise in strategy setting and operational excellence, with a key focus in country operations and business unit leadership across specialty markets.

Driven to do meaningful work every single day.

Related Story

Diseases

 Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen | Pharmtech Focus

Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

May 6 2022

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]

Clinical Trials

 Calquence Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia | Pharmtech Focus

Calquence Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia and Sustained Patient Benefit at Four Years in the Front-line Setting

June 7 2021

Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior […]

Diseases

 Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-stage EGFR-mutated Lung Cancer | Pharmtech Focus

Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-stage EGFR-mutated Lung Cancer

May 28 2021

AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult […]

Diseases

 Imfinzi and Tremelimumab with Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage Iv Non-small Cell Lung Cancer | Pharmtech Focus

Imfinzi, Tremelimumab and Chemotherapy Demonstrated Significant Benefit Versus Chemotherapy Alone

May 7 2021

POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy […]